共 50 条
A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea
被引:7
|作者:
Chen, Yufan
[1
]
Watson, Tina R.
[1
]
Criss, Steven D.
[1
]
Eckel, Andrew
[1
]
Palazzo, Lauren
[1
]
Sheehan, Deirdre F.
[1
,3
]
Kong, Chung Yin
[1
,2
]
机构:
[1] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
来源:
基金:
美国国家卫生研究院;
关键词:
SMOKING PREVALENCE;
UNITED-STATES;
MORTALITY;
TRENDS;
CT;
OUTCOMES;
PROGRAM;
MODELS;
IMPACT;
NLST;
D O I:
10.1371/journal.pone.0220610
中图分类号:
O [数理科学和化学];
P [天文学、地球科学];
Q [生物科学];
N [自然科学总论];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
More than 50% of the world's lung cancer cases occur in Asia and more than 20% of cancer deaths in Asia are attributable to lung cancer. The U. S. National Lung Screening Trial has shown that lung cancer screening with computed tomography ( CT) can reduce lung cancer deaths. Using the Lung Cancer Policy Model-Asia ( LCPM-Asia), we estimated the potential mortality reduction achievable through the implementation of CT-based lung cancer screening in China, Japan, Singapore, and South Korea. The LCPM-Asia was calibrated to the smoking prevalence of each of the aforementioned countries based on published national surveys and to lung cancer mortality rates from the World Health Organization. The calibrated LCPM-Asia was then used to simulate lung cancer deaths under screening and no-screening scenarios for the four countries. Using screening eligibility criteria recommended by the U. S. Centers for Medicare & Medicaid Services ( CMS), which are based on age and smoking history, we estimated the lung cancer mortality reduction from screening through year 2040. By 2040, lung cancer screening would result in 91,362 life-years gained and 4.74% mortality reduction in South Korea; 290,325 life-years gained and 4.33% mortality reduction in Japan; 3,014,215 life-years gained and 4.22% mortality reduction in China; and 8,118 life-years gained and 3.76% mortality reduction in Singapore. As for mortality reduction by smoker type, current smokers would have the greatest mortality reduction in each country, ranging from 5.56% in Japan to 6.86% in Singapore. Among the four countries, lung cancer screening under CMS eligibility criteria was most effective in South Korea and least effective in Singapore. Singapore's low smoking prevalence and South Korea's aging population and higher smoking prevalence may partially explain the discrepancy in effectiveness. CT screening was shown to be promising as a means of reducing lung cancer mortality in the four countries.
引用
收藏
页数:16
相关论文